Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles J Ryan

Showing results (21-30 of 204) with videos related to

Pageof 21
Sort By:
The Urologic Clinics of North America|October 23, 2012
Targeting the androgen receptorTerence W Friedlander, Charles J Ryan
Journal of the National Comprehensive Cancer Network : JNCCN|October 3, 2009
The selection of hormonal therapy in prostate cancer: who, when, and for how long?Charles J Ryan, Eric J Small
Urology|January 30, 2004
Role of secondary hormonal therapy in the management of recurrent prostate cancerCharles J Ryan, Eric J Small
Current Opinion in Oncology|April 9, 2005
Progress in detection and treatment of prostate cancerCharles J Ryan, Eric J Small
Expert Review of Anticancer Therapy|February 19, 2008
Therapies in development for castrate-resistant prostate cancerAndrea L Harzstark, Charles J Ryan
The Journal of Urology|July 24, 2007
Prostate specific antigen only androgen independent prostate cancer: natural history, challenges in management and clinical trial designCharles J Ryan, Tomasz M Beer
Current Opinion in Urology|April 4, 2009
Novel secondary hormonal therapy in advanced prostate cancer: an updateEliezer M Van Allen, Charles J Ryan
The Oncologist|June 19, 2016
DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic OpportunitiesMallika Dhawan, Charles J Ryan, Alan Ashworth
Urologic Oncology|May 9, 2006
Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationaleCharles J Ryan, Amy M Lin, Eric J Small
The Lancet. Oncology|October 5, 2007
Androgen-response elements in hormone-refractory prostate cancer: implications for treatment developmentAndrew C Hsieh, Eric J Small, Charles J Ryan
Pageof 21

Showing results (21-30 of 204) with videos related to

Sort By:
Pageof 21
The Urologic Clinics of North America|October 23, 2012
Targeting the androgen receptorTerence W Friedlander, Charles J Ryan
Journal of the National Comprehensive Cancer Network : JNCCN|October 3, 2009
The selection of hormonal therapy in prostate cancer: who, when, and for how long?Charles J Ryan, Eric J Small
Urology|January 30, 2004
Role of secondary hormonal therapy in the management of recurrent prostate cancerCharles J Ryan, Eric J Small
Current Opinion in Oncology|April 9, 2005
Progress in detection and treatment of prostate cancerCharles J Ryan, Eric J Small
Expert Review of Anticancer Therapy|February 19, 2008
Therapies in development for castrate-resistant prostate cancerAndrea L Harzstark, Charles J Ryan
The Journal of Urology|July 24, 2007
Prostate specific antigen only androgen independent prostate cancer: natural history, challenges in management and clinical trial designCharles J Ryan, Tomasz M Beer
Current Opinion in Urology|April 4, 2009
Novel secondary hormonal therapy in advanced prostate cancer: an updateEliezer M Van Allen, Charles J Ryan
The Oncologist|June 19, 2016
DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic OpportunitiesMallika Dhawan, Charles J Ryan, Alan Ashworth
Urologic Oncology|May 9, 2006
Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationaleCharles J Ryan, Amy M Lin, Eric J Small
The Lancet. Oncology|October 5, 2007
Androgen-response elements in hormone-refractory prostate cancer: implications for treatment developmentAndrew C Hsieh, Eric J Small, Charles J Ryan
Pageof 21